{"id":"W3130253087","doi":"10.1158/1078-0432.ccr-20-4338","title":"FDA Approval Summary: Nivolumab with Ipilimumab and Chemotherapy for Metastatic Non–small Cell Lung Cancer, A Collaborative Project Orbis Review","year":2021,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Canada","funders":"U.S. Food and Drug Administration; National Institutes of Health","keywords":"Nivolumab; Ipilimumab; Medicine; Oncology; Chemotherapy; Cancer; Lung cancer; Internal medicine; Immunotherapy; Intensive care medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003002024,0.0003003256,0.001108964,0.0001214457,0.0002435208,0.00008225176,0.0002160019,0.0001450376,0.0004956704],"category_scores_gemma":[0.0003774515,0.0002198559,0.000240654,0.001638321,0.0006323252,0.00009388565,0.00009369054,0.0007845,0.00000234844],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004046205,"about_ca_system_score_gemma":0.008387052,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001610975,"about_ca_topic_score_gemma":0.002380299,"domain_scores_codex":[0.9962588,0.0005548621,0.0007649863,0.0009809615,0.0007134053,0.0007269999],"domain_scores_gemma":[0.9960945,0.001060881,0.000199766,0.0006032634,0.001774833,0.0002667762],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.06830473,0.002365675,0.02840776,0.03800121,0.004024669,0.0003564786,0.00163892,0.00000219699,0.004780983,0.00004231181,0.470227,0.3818481],"study_design_scores_gemma":[0.07012782,0.009706341,0.008915745,0.02165314,0.001805259,0.00009010796,0.002511105,0.00130847,0.01107389,0.00008114926,0.8715393,0.001187673],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.3480195,0.6035262,0.0002985006,0.03045595,0.0004955545,0.01400476,0.0005748682,0.00008537498,0.002539304],"genre_scores_gemma":[0.03319548,0.9226077,0.007059762,0.009449191,0.0007908839,0.007724126,0.0001526611,0.0002000102,0.01882021],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.4013123,"threshold_uncertainty_score":0.9972345,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1427796876373779,"score_gpt":0.5034665726369157,"score_spread":0.3606868849995378,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}